XML 34 R7.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Note 1 - Nature of the Business | 12 Months Ended
--- | ---
Dec. 31, 2023
Notes to Financial Statements |
Nature of Operations [Text Block] |
1. | Nature of the business
BeyondSpring Inc. (the “Company”) was incorporated in the Cayman Islands on November 21, 2014. The Company and its subsidiaries (collectively, the “Group”) are principally engaged in clinical stage biopharmaceutical activities focused on the development of innovative cancer therapies. The Company is under the control of Mr. Linqing Jia and Dr. Lan Huang as a couple (collectively, the “Founders”) since its incorporation. On March 14, 2017, the Company completed its initial public offering (“IPO”) on the NASDAQ Capital Market. On May 21, 2019, the Company entered into a sales agreement with Jefferies LLC (“Jefferies”) to act as an agent in selling the Company’s ordinary shares in an at-the-market (“ATM”) offering program. As of December 31, 2023, the Company received aggregate gross proceeds of $13,185 on 630,228 ordinary shares sold in respect thereof. On June 14, 2019 and July 3, 2019, certain investors led by Shenzhen Efung 9th Venture Investment Center (Limited Partnership) (“Efung Capital”) entered into investment agreements with Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”), a subsidiary of the Company, to invest $14,537 (RMB100,000) for a total of 4.76% equity interest of Wanchunbulin. In 2019, the Company received aggregate gross proceeds of $10,083 (RMB70,000) from this equity financing. On March 22, 2022, Wanchun Hongji (Dalian) Pharmaceuticals Ltd. was incorporated in the People’s Republic of China (“PRC”) as a wholly owned subsidiary of SEED Therapeutics Inc. In March 2023, BeyondSpring Pharmaceuticals Australia PTY Ltd. (BeyondSpring Australia), a wholly owned subsidiary of the Company, was deregistered in Australia. As of December 31, 2023, the subsidiaries of the Company are as follows:
Name of company |  | Place of incorporation |  | Date of incorporation |  | Percentage of ownership by the Group |  | Principal activities
BeyondSpring Pharmaceuticals Inc. (“BeyondSpring US”) |  | Delaware, U.S. |  | June 18, 2013 |  | 100% |  | Clinical trial activities
BeyondSpring Ltd. |  | The British Virgin Islands (“BVI”) |  | December 3, 2014 |  | 100% |  | Holding company
BeyondSpring (HK) Limited (“BeyondSpring HK”) |  | Hong Kong |  | January 13, 2015 |  | 100% |  | Holding company
Wanchun Biotechnology Limited (“BVI Biotech”) |  | BVI |  | April 1, 2015 |  | 100% |  | Holding company
Wanchun Biotechnology (Dalian) Ltd. (“Wanchun Dalian”) |  | PRC |  | April 23, 2015 |  | 100% |  | Holding company
Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”) |  | PRC |  | May 6, 2015 |  | 57.97% |  | Clinical trial activities
Beijing Wanchun Pharmaceutical Technology Ltd. (“Beijing Wanchun”) |  | PRC |  | May 21, 2018 |  | 57.97% |  | Holding company
SEED Therapeutics Inc. (“SEED”) |  | BVI |  | June 25, 2019 |  | 55.05% |  | Pre-clinical development activities
SEED Technology Limited (“SEED Technology”) |  | BVI |  | December 9, 2019 |  | 57.97% |  | Holding company
SEED Therapeutics US, Inc. (“SEED US”) |  | Delaware, U.S. |  | November 25, 2020 |  | 55.05% |  | Pre-clinical development activities
Wanchun Hongji (Dalian) Pharmaceuticals Ltd. (“Wanchun Hongji”) |  | PRC |  | March 22, 2022 |  | 55.05% |  | Pre-clinical development activities
BEYONDSPRING INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 AND 2021 (Amounts in thousands of U.S. Dollars (“$”) and Renminbi (“RMB”), except for number of shares and per share data)

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details
Name: | us-gaap_NatureOfOperations
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration